AI Drug Discovery Milestone: First Fully AI-Designed Molecule Passes FDA Phase III Trial

Insilico Medicine's INS018_055 becomes the first candidate drug fully designed by AI throughout the entire drug discovery process, successfully passing FDA Phase III clinical trials, with potential approval by the end of 2026. Meanwhile, AI-discovered drugs from Recursion Pharmaceuticals and Exscientia have also entered late-stage clinical trials. This article analyzes the technological breakthroughs in AI-driven drug discovery, estimates how AI will reshape the trillion-dollar pharmaceutical market, and highlights AI drug discovery targets that investors are watching.